undamentalytics Newsletter
Sign in

Bionano Genomics, Inc. income statement

In fiscal 2025, Bionano Genomics, Inc. reported revenue of $28.5m, down 7.4% on the year before, operating income of −$33.3m (a -116.9% margin) and net income of −$26.4m, or −$4.85 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1012109182836312930
Cost of revenue6976142227301516
Gross profit3333461001314
Research and development129910224954251112
Selling, general and administrative14142031588993523534
Operating income−23−20−26−39−77−132−215−104−33−32
Interest expense1123105———
Income before tax−23−18−30−41−78−131−232−112−26−32
Income tax0000−620000
Net income−23−18−30−41−72−133−232−112−26−32
Diluted EPS−$2595.00−$783.00−$1194.00−$234.00−$15.60−$274.80−$408.60−$88.13−$4.85—
Diluted shares (average)—24m25m174m461m482m—1m5m—
EBITDA−22−19−25−37−74−122−202−90−24−24

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BNGO vs MXCTBNGO vs RPIDBNGO vs OABI

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Bionano Genomics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bionano Genomics, Inc.